Thank you for visiting -
BiotecMax™ BiotecNova™ BiotecHope™ BiotecHeart™ BiotecWars™ BiotecData™ BiotecAlpha™ BiotechStorm™ BiotechVortex™ Biotech-Wars™ BioHazard2020
Since 2010 I have been focused on researching and investing in Pharmaceutical, Biotech, and Medical Technology companies. I focus on companies that are developing medicines or have developed medicines for diabetes, Alzheimer’s, cancer, hepatitis, Crohn’s disease, and others. I have been very successful with this investment strategy since 2009. My first successful healthcare/biotech investment was on March 12th, 2009 when Roche® purchased a biotechnology company that I held stock in - Genentech®. Roche’s purchase of Genentech for $46.8 Billion was the motivation to review the entire healthcare sector. Highlighted below are companies that I have or have had long positions in since 2010 and I will occasionally trade in and out these companies. From my perspective the biotech sector has been on a bull run since 2009. On February 7th, 2018, 2 days after the ^VIX inspired high volatility crash/correction on February 5th and 6th of 2018, I again went “all in” on the Healthcare sector. More importantly the cancer death rate in the U.S. fell 13% from 2004 to 2013 according to those who track such information.
Please be advised that I am not a financial adviser/investment adviser, and I have no business relationship with any of the company’s who are mentioned below. I have worked for Unilever®, Grey Advertising®, Hasbro®, Toys R Us® and other companies prior to 2010. I consider myself, insightful regarding trends and products, market timing, identifying long-term value situations, long-term brand development, and identifying technologies and products that will be highly profitable. I do not “blog” often, as I spend more time processing information then communicating data. I have been following many Seeking Alpha writers as a member since 2012. I also gain information/data/charts from many other sources. And have many business and company alerts directly sent to me on their products, and product tests involving new medicines. These are extraordinary times for investing and processing new products and ventures and is not limited to the healthcare sector. However, the amounts of money being devoted to new medical technologies and new medicines is remarkable.
As of 9/24/2021 I remain 100% invested in biotech/medtech companies, My reasons are as follows:
1. Healthcare is the right category for growth over next 10+ years, as I agree with comments from Russ Koesterich of BlackRock® on September 19, 2018 www.blackrock.com/...
"At $3.5 trillion per year, total healthcare spending (public and private) makes up roughly 20% of the U.S. economy. The nation's 80 million baby boomers provide a stable source of ongoing revenue growth for healthcare companies throughout the value chain. Demographic tailwinds are widely expected to continue to propel this secular story in the United States."
3. Healthcare is also a defensive category if things turn south as many company pipelines and product development will continue to progress.
4. The biotech sector is increasingly becoming an effort to seek stronger partnership (seeking biotech partnerships). Many companies are developing new drugs that can in many instances work better in combination with other successful/newer drugs or help other drugs work better against specific medical issues when used in combination.
5. Both biotech and medtech companies are also increasing their partnerships with biotechnology focused colleges and medical universities/hospitals towards successful co-product development partnerships. This is occurring on a global basis. The www.biotechVORTEX.com section of this site covers these partnerships and mergers in the biopharma sector.
my current holdings as of 9/24/2021 =
Before February 5th, 2018 I was a passive investor, no longer. I am now an active supporter of all the healthcare, medical, and biotech companies that I hold stock in. Please be advised that this is not investment advise, these are my investments. Thank you for visiting seeking biotech alpha and please feel free to send me comments/feedback/questions - to firstname.lastname@example.org
My best to all in 2021, as we will continue to see chaotic volatility again and we will definitely see vilification of the entire healthcare sector by politicos, for the fourth consecutive year. We will also see continued attacks by state AG's filing lawsuits against bio-pharma/biotech companies for huge sums to off-set their declining state finances. There is no doubt 2020 will go down as the worst year for bio-pharma companies from a political/PR standpoint as the 2020 election year brought the greatest number of targeted political ads against the bio-pharma sector. Positive product news regarding the virus has had little effect on countering the continued vilification of the bio-pharma sector in 2020. I keep track of this at www.biotech-WARS.com and www.biotecWARS.com
I also keep track of the SARS-CoV2 virus and Covid-19 news and updates here at www.biohazard2020.com / www.BiotechSTORM.com and will continue to do so in 2021. This is the latest page I have on the www.BiotechSTORM.com = https://seekingbiotechalpha.com/biohazard2021-5-1
Bio-Pharma/MedTech companies that I invest in = I keep track of their products/meds at the www.biotecMAX.com section of this site, most recent info is here = https://seekingbiotechalpha.com/2021-2- for many of the most successful meds I keep track of at www.biotecNOVA.com
These are the primary companies I invest in and keep track of;
VAR ABBV, ABMD, ABT, AMGN, AMRN, AZN, BGNE, BIIB, BLUE, BMRN, BMY, GILD, ISRG, JNJ, LLY, MDT, MRK, NVS, PFE, REGN, RHHBY, SGEN, SRPT, VRTX (ILMN) (PODD) (DXCM) (RARE) VCYT NVAX XLRN SRNE GALT BCTX BNTX MRNA
God bless all the healthcare professionals battling Covid-19 around the world, thank you.
Thank you for visiting www.seekingbiotechalpha.com and all the links below.
comments and blogs posted on seeking alpha
dan watson's real time 24/7 portfolio - seeking biotech alpha @ GuruFocus
PhRMA member companies are committed to helping patients make more informed health care decisions by providing more transparency about medicine costs. This, along with the development of the Medicine Assistance Tool, provides patients with the information they need to make more educated health care decisions.
PhRMA’s Medicine Assistance Tool (MAT) is a search engine designed to help patients, caregivers and health care providers learn more about the resources available through the various biopharmaceutical industry programs. MAT is not its own patient assistance program, but rather a search engine for many of the patient assistance resources that the biopharmaceutical industry offers.
A Bioincubator is a launch-pad structure for entrepreneurs to make their project in the sciences real. In Europe, we have many incubators within each industry, responsible for strategic investment, development and providing a support network for start-ups.
Sectors: Pharmaceutical and Agricultural.
Sectors: Biotherapies, Genetics, Biotechnology
Sectors: Life Sciences
Sectors: Agrifood, Bioeconomy and Life Sciences
Sectors: Biotechnology and Health
Sectors: Healthcare and Pharmaceuticals
Finally, this short list shows you that Europe count a lot of great bioincubators. This means european Bio-entrepreneurs can find ideal places to start their business, from Sweden to Spain.
Overhauling the site was a project that took decades and millions of dollars. The Delaware River Port Authority allocated $8 million for demolition of the prison, and the New Jersey Economic Development Authority (EDA) supplemented that with $5 million in planning and infrastructure grants.
The Wells Fargo Regional Foundation kicked in $750,000 for a neighborhood planning grant, and the William Penn Foundation added another quarter-million dollars for the bikeway improvements.
There are plans to construct a mixed-use commercial-residential development on the surrounding property at Cooper’s Poynt, but the EDA still hasn’t found qualified developers to take on the project.
Maureen Hassett, EDA senior vice president of governance, communications, and strategic initiatives, said the agency is evaluating options for the land, which is still owned by the New Jersey Department of Corrections.
Rodney Sadler, Executive Director of the Save Our Waterfront neighborhood coalition, recollected the years of work that went into salvaging the property, from opposing construction of the prison to the day it was leveled.
“It made a difference,” Sadler said. “It made it possible.”
A Prison Falls, a Playground Rises in North Camden
Cooper’s Poynt Playground. Credit: Matt Skoufalos.
Copyright © 2018 seeking biotech alpha - All Rights Reserved. City Photos from Pixabay
Powered by GoDaddy Website Builder